Squarepoint
LAB icon

Squarepoint’s Standard BioTools LAB Stock Holding History

Squarepoint’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$228K Buy
+277,375
New +$262K ﹤0.01% 3987
2025
Q3 		– Sell
-43,253
Closed -$51.9K – 4692
2025
Q2 		$51.9K Buy
+43,253
New +$47.9K ﹤0.01% 4297
2024
Q4 		– Sell
-236,396
Closed -$456K – 5294
2024
Q3 		$456K Sell
236,396
-69,120
-23% -$135K ﹤0.01% 3169
2024
Q2 		$541K Buy
305,516
+172,738
+130% +$422K ﹤0.01% 3017
2024
Q1 		$360K Buy
132,778
+96,397
+265% +$233K ﹤0.01% 3269
2023
Q4 		$80.4K Buy
+36,381
New +$77.7K ﹤0.01% 3788
2023
Q2 		– Sell
-11,138
Closed -$21.7K – 3804
2023
Q1 		$21.7K Buy
+11,138
New +$22K ﹤0.01% 3128
2022
Q3 		– Sell
-12,492
Closed -$20K – 3219
2022
Q2 		$20K Buy
+12,492
New +$30.9K ﹤0.01% 2772
2022
Q1 		– Sell
-129,734
Closed -$509K – 3216
2021
Q4 		$509K Buy
129,734
+101,064
+353% +$473K ﹤0.01% 2132
2021
Q3 		$189K Buy
+28,670
New +$189K ﹤0.01% 2515
2021
Q1 		– Sell
-67,577
Closed -$405K – 3377
2020
Q4 		$405K Buy
67,577
+12,277
+22% +$80.7K ﹤0.01% 1971
2020
Q3 		$411K Sell
55,300
-71,127
-56% -$491K 0.01% 1580
2020
Q2 		$507K Buy
126,427
+109,351
+640% +$381K 0.01% 1310
2020
Q1 		$43K Sell
17,076
-343,643
-95% -$1.13M ﹤0.01% 1732
2019
Q4 		$1.25M Sell
360,719
-53,421
-13% -$188K 0.01% 1196
2019
Q3 		$1.92M Buy
414,140
+235,840
+132% +$1.86M 0.02% 865
2019
Q2 		$2.2M Buy
178,300
+58,992
+49% +$751K 0.02% 794
2019
Q1 		$1.59M Buy
119,308
+46,319
+63% +$488K 0.02% 877
2018
Q4 		$629K Buy
+72,989
New +$569K 0.01% 1138
2018
Q3 		– Sell
-24,795
Closed -$148K – 2102
2018
Q2 		$148K Buy
+24,795
New +$141K ﹤0.01% 1587
2017
Q1 		– Sell
-18,936
Closed -$138K – 1730
2016
Q4 		$138K Buy
+18,936
New +$119K 0.01% 1563
2016
Q3 		– Sell
-13,400
Closed -$121K – 1142
2016
Q2 		$121K Buy
+13,400
New +$126K 0.01% 962

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Squarepoint's LAB Position: Q2 2026 in Review

Squarepoint opened a new position in Standard BioTools (LAB) in Q2 2026: 277,375 shares worth $228K. The stake represents ﹤0.01% of the portfolio and ranks #3987 among its holdings. This is a return to the name: Squarepoint previously reported a position in LAB as recently as Q2 2025.

Squarepoint first reported a position in LAB in Q2 2016 and has held it in 22 quarters since. The position peaked at $2.2M in Q2 2019. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Squarepoint held 277,375 shares of Standard BioTools worth $228K as of Q2 2026.
  • Standard BioTools was a new Squarepoint position in Q2 2026.
  • Standard BioTools made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3987 holding.
  • Squarepoint first reported a position in Standard BioTools in Q2 2016 and has held it in 22 quarters since.
  • Squarepoint's Standard BioTools position peaked at $2.2M in Q2 2019.
  • 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.